Loading organizations...
§ Private Profile · Austin, TX, USA
Cloud AI platform developer automating microscopy image analysis and deep AI model interpretation for life science research.
Biodock has raised $2.0M across 1 funding round.
Key people at Biodock.
Biodock was founded in 2020 by Nurlybek Mursaliyev (Founder).
Biodock has raised $2.0M in total across 1 funding round.
Based in Austin, Texas, Biodock develops a cloud-based artificial intelligence platform that automates microscopy image analysis for life science researchers and pharmaceutical scientists. The enterprise software-as-a-service solution allows users to train, run, and interpret complex deep learning models on biological images and sequencing data without requiring advanced coding expertise. Operating with a team of approximately eight full-time employees, the company provides auto-scaling storage and GPU compute infrastructure that was utilized by more than 100 organizations as of March 2021. The startup has raised $2.1 million in total funding from prominent institutional venture capital backers including Andreessen Horowitz and Y Combinator. Its image processing technology serves academic research laboratories alongside major global biotechnology and pharmaceutical enterprise customers such as Genentech, CSL Behring, and Vaxxas. Biodock was founded in 2020 by Nurlybek Mursaliyev and Michael Lee.
Biodock has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in March 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2021 | $2M Seed | Andreessen Horowitz | Accel, Addition, Alumni Ventures, BoxGroup, Cathay Innovation, Cedar Capital Group, Curie.bio, DST Global, Equal Ventures, Flourish Ventures, Global Founders Capital, Jetstream, Monashees, Hans Tung, Operator Partners, Silence, Union Square Ventures, Vast Ventures, Voyager Ventures, WGI Group, Yellow Ventures, Guilherme Bonifacio, Josh Abramowitz, Kiran Bhatraju, Steve Martocci, Teddy Citrin, TOM Mcinerney, John Curtius, Zach Weinberg, Soma Capital, TQ Ventures | Announced |
Key people at Biodock.
Biodock was founded in 2020 by Nurlybek Mursaliyev (Founder).
Biodock has raised $2.0M in total across 1 funding round.
Biodock's investors include Andreessen Horowitz, Accel, Addition, Alumni Ventures, BoxGroup, Cathay Innovation, Cedar Capital Group, Curie.Bio, DST Global, Equal Ventures, Flourish Ventures, Global Founders Capital.
Biodock is a cloud-based AI platform that automates microscopy image analysis, reducing what traditionally takes months of manual work to just minutes. It leverages deep learning to provide scientists—primarily in pharmaceutical and biological research—with highly accurate, scalable, and fast analysis of complex biological images. The platform supports a wide range of biological image types and offers features like AI-assisted labeling, customizable metrics, and enterprise-grade security, enabling researchers to accelerate their R&D workflows and derive therapeutic insights more efficiently[1][2][4].
Founded in 2020 and based in Austin, Texas, Biodock serves academic and enterprise scientists, including pharmaceutical companies and biotech firms. Its product solves the problem of time-consuming, labor-intensive microscopy image analysis by automating labeling and interpretation with AI models that can be trained and deployed rapidly without coding expertise. Biodock has demonstrated strong growth momentum, with over 100 organizations using its platform, including notable names like Genentech and CSL Behring, and has raised $2.1 million in funding from investors such as Andreessen Horowitz[2][3].
Biodock was founded in 2020 by Nurlybek Mursaliyev, who holds a Ph.D. in Cell and Molecular Biology from Stanford University. His research focus on stem cell biology and embryo development exposed him firsthand to the challenges of microscopy image analysis, inspiring the creation of Biodock. Prior to Biodock, Mursaliyev co-founded a med-tech startup, SmartLens, but chose to focus on his Ph.D. before launching Biodock. The company entered Y Combinator’s Winter 2021 batch, which helped accelerate its development and market entry[1][2].
Early traction came from rapid adoption by pharmaceutical and biotech researchers who recognized the platform’s ability to automate and improve the accuracy of microscopy analysis. This pivotal validation helped Biodock secure seed funding and build a growing user base in both academic and enterprise sectors[2].
Biodock rides the growing trend of applying AI and cloud computing to accelerate biomedical research and drug discovery. The timing is critical as the pharmaceutical industry increasingly relies on high-throughput microscopy and imaging data, which traditionally require extensive manual analysis. Advances in deep learning and cloud infrastructure have made scalable, automated image analysis feasible, addressing a major bottleneck in R&D workflows.
Market forces such as rising demand for precision medicine, increasing volumes of biological imaging data, and the need for faster therapeutic development favor Biodock’s solution. By enabling scientists to extract insights faster and more accurately, Biodock influences the broader ecosystem by pushing the adoption of AI-driven automation in life sciences, potentially shortening drug development cycles and improving research reproducibility[1][2][4].
Biodock is well-positioned to expand its footprint in pharmaceutical and biotech research by continuing to enhance its AI capabilities and scaling its cloud infrastructure. Future trends shaping its journey include the integration of multi-omics data, increased adoption of AI in regulatory science, and growing demand for remote, cloud-based research tools.
As Biodock matures, it may evolve into a critical platform for AI-powered biological image analysis, influencing how academic and enterprise scientists conduct microscopy-based research. Its ability to democratize deep learning for biological images without requiring coding expertise could broaden its user base and accelerate innovation in drug discovery and life sciences.
In summary, Biodock’s mission to automate and accelerate microscopy analysis with cloud AI addresses a significant pain point in biomedical research, leveraging cutting-edge technology and strong market demand to drive growth and impact[1][2][4].
